Poland· PL-100511687
Alhemo
A concizumab product containing concizumabum, registered in Poland by Novo Nordisk A/S. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Concizumab is registered in 11 of 19 countries.
Countries holding a registration under ATC B02BX10 (concizumab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Concizumab · ATC B02BX10
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Statesprice
Price per daily dose
What a daily dose of concizumab costs, country by country.
Normalised to the WHO defined daily dose (14 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Concizumab · price per daily dose (14 mg)
USD · FX 28 Sept 2026
- CH Switzerland$1227.21
The record
At a glance
URPL (Poland)- Active substance
- Concizumabum
- Manufacturer
- Novo Nordisk A/S
- Country
- Poland (PL)
- ATC code
- B02BX10
- ATC class
- Concizumab
- Defined daily dose
- 14 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05712249130596
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Concizumab in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaALHEMONovo Nordisk A/S, Bagsvaerd
- BelgiumAlhemo 60 mg/1.5 mlNovo Nordisk
- SwitzerlandAlhemo
- SpainALHEMO 60 MG/1,5 ML SOLUCION INYECTABLE EN PLUMA PRECARGADANovo Nordisk A/S
- IcelandAlhemoNovo Nordisk A/S*
- SwedenAlhemo 60 mg/1,5 ml Injektionsvätska, lösning i förfylld injektionspennaNovo Nordisk A/S
- FinlandAlhemoNovo Nordisk A/S
- IrelandAlhemo 15 mg/1.5 mL solution for injection in pre-filled penNovo Nordisk A/S
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Alhemo
- Norway · Alhemo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/67769446-9b48-4214-8f6b-5f11b168d1f4 GET /v1/drugs/67769446-9b48-4214-8f6b-5f11b168d1f4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań we wstrzykiwaczu",
"source": "urpl",
"strength": "60 mg/1,5 ml",
"packaging": "Rpz ¦ EU/1/24/1881/004 ¦ 159900\n5 wstrzykiwaczy 1,5 ml\n05712249130596 ¦ Rpz ¦ EU/1/24/1881/003 ¦ 159901\n1 wstrzykiwacz 1,5 ml",
"substance": "Concizumabum 60 mg/1.5 ml",
"common_name": "Concizumabum",
"pl_product_id": "100511687",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about concizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.